<DOC>
	<DOCNO>NCT00049413</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop cancer cell divide stop grow die . Monoclonal antibody locate cancer cell either kill deliver cancer-killing substance without harm normal cell . Combining chemotherapy monoclonal antibody therapy may kill cancer cell . PURPOSE : Phase II trial study effectiveness combine pentostatin cyclophosphamide rituximab treat patient chronic lymphocytic leukemia lymphocytic lymphoma .</brief_summary>
	<brief_title>Combination Chemotherapy Rituximab Treating Patients With Chronic Lymphocytic Leukemia Lymphocytic Lymphoma</brief_title>
	<detailed_description>OBJECTIVES : - Determine efficacy pentostatin , cyclophosphamide , rituximab , term response rate , time treatment failure , time disease progression , durability response , overall survival , patient B-cell chronic lymphocytic leukemia small B-cell lymphocytic lymphoma . - Determine safety regimen , term acute , subacute , chronic toxicity , patient treat regimen . OUTLINE : This multicenter study . Patients stratify accord prior chemotherapy ( prior chemotherapy chronic lymphocytic leukemia v prior purine analog-based therapy [ fludarabine cladribine ] alkylator therapy v prior alkylator-based therapy [ chlorambucil cyclophosphamide ] prior purine analog therapy v prior therapy alkylators purine analog , combination therapy ) . - First course : Patients receive rituximab IV 1-4 hour day 1-3 pentostatin IV 10-30 minute cyclophosphamide IV 30-60 minute day 1 . - All subsequent course : Patients receive rituximab IV 60 minute , pentostatin IV 10-30 minute , cyclophosphamide IV 30-60 minute day 1 . Treatment repeat every 3 week 6 course absence disease progression unacceptable toxicity . Patients follow every 3 month 5 year . PROJECTED ACCRUAL : A total 160-240 patient ( 40-60 per stratum ) accrue study .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Pentostatin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis Bcell chronic lymphocytic leukemia ( CLL ) small Bcell lymphocytic lymphoma ( SLL ) following : Lymph node biopsy interpreted SLL consistent CLL following : Peripheral lymphocyte count great 5,000/mm^3 small moderate peripheral lymphocytes 55 % prolymphocytes Bone marrow aspirate contain least 30 % lymphoid cell Immunophenotypic evaluation peripheral blood lymphocyte demonstrate monoclonality B lymphocytes follow : CD19 CD20 coexpressed CD5 antigen absence panT cell marker ( e.g. , CD2 CD3 ) Expression CD23 CLL cell Dim Bcell expression kappa lambda light chain Measurable disease follow : 1 lymph node least 1.5 cm CT scan Splenomegaly CT scan Peripheral lymphocyte count great 5,000/mm3 coexpression CD5 Bcell marker Bone marrow aspirate least 30 % lymphoid cell No mantle cell lymphoma PATIENT CHARACTERISTICS : Age 18 Performance status ECOG 02 Life expectancy At least 2 year Hematopoietic See Disease Characteristics No immune thrombocytopenia No hemolytic anemia Hepatic Bilirubin great 3 time upper limit normal ( ULN ) SGOT great 3 time ULN ( unless due hemolysis CLL ) No hepatitis Renal Creatinine great 1.5 time ULN Cardiovascular No cardiac dysfunction No New York Heart Association class III IV heart disease No myocardial infarction within past month Other HIV negative No active acute chronic infection No immunosuppressive diseases No autoimmune disorder No secondary malignancy project limit life expectancy Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception PRIOR CONCURRENT THERAPY : Biologic therapy See Chemotherapy No prior rituximab At least 4 week since prior biologic therapy Chemotherapy At least 4 week since prior chemotherapy No prior combination chemotherapy rituximab antibody therapy No prior combination chemotherapy comprise alkylating agent purine nucleoside analog ( i.e. , cyclophosphamide chlorambucil combination fludarabine , cladribine , pentostatin ) No prior pentostatin Endocrine therapy At least 4 week since prior corticosteroid No concurrent supraphysiologic dose corticosteroid Radiotherapy At least 4 week since prior radiotherapy Surgery At least 4 week since prior major surgery Other No concurrent immunosuppressive therapy ( e.g. , cyclosporine )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2011</verification_date>
	<keyword>B-cell chronic lymphocytic leukemia</keyword>
	<keyword>refractory chronic lymphocytic leukemia</keyword>
	<keyword>stage I chronic lymphocytic leukemia</keyword>
	<keyword>stage II chronic lymphocytic leukemia</keyword>
	<keyword>stage III chronic lymphocytic leukemia</keyword>
	<keyword>stage IV chronic lymphocytic leukemia</keyword>
	<keyword>contiguous stage II small lymphocytic lymphoma</keyword>
	<keyword>noncontiguous stage II small lymphocytic lymphoma</keyword>
	<keyword>recurrent small lymphocytic lymphoma</keyword>
	<keyword>stage I small lymphocytic lymphoma</keyword>
	<keyword>stage III small lymphocytic lymphoma</keyword>
	<keyword>stage IV small lymphocytic lymphoma</keyword>
</DOC>